Navigation Links
In asthma, it's not just what you smell, but what you think you smell
Date:7/22/2014

PHILADELPHIA (July 22, 2014) New research from the Monell Center reveals that simply believing that an odor is potentially harmful can increase airway inflammation in asthmatics for at least 24 hours following exposure. The findings highlight the role that expectations can play in health-related outcomes.

"Asthmatics often are anxious about scents and fragrances. When we expect that an odor is harmful, our bodies react as if that odor is indeed harmful," said study lead author Cristina Jan, PhD, a Monell physiologist. "Both patients and care providers need to understand how expectations about odors can influence symptoms of the disease."

Asthma is a chronic inflammatory disorder of the lungs. According to the National Institutes of Health, over 25 million Americans have the disease, which can interfere with quality of life. The airways of asthmatics are sensitive to 'triggers' that further inflame and constrict the airways, making it difficult to breathe. There are many different types of triggers, including pollen, dust, irritating chemicals, and allergens. Strong emotions and stress also can act to trigger asthma symptoms.

Because asthma has no cure, it is important for individuals with the disease to understand how to manage their symptoms to help prevent severe asthma attacks.

Many health organizations list scents and fragrances as asthma triggers, leading patients to become anxious when exposed to environmental odors. The current research was conducted to determine whether odor-triggered asthma symptoms can be elicited or worsened by associated negative expectations.

In the study, published online ahead of print in the Journal of Psychosomatic Research, 17 individuals characterized as moderate asthmatics were exposed to the odor phenylethyl alcohol (PEA) for 15 minutes. Often described as rose-smelling, PEA is regarded as a 'pure' odorant with no associated physiological irritant qualities.

Ei
'/>"/>

Contact: Leslie Stein
stein@monell.org
267-519-4707
Monell Chemical Senses Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Rethinking the reef
2. Stanford researchers rethink natural habitat for wildlife
3. How coughs and sneezes float farther than you think
4. Thinking it through: Scientists seek to unlock mysteries of the brain
5. Climate engineering -- what do the public think?
6. Hoyos Labs, a Digital Infrastructure Security Company, Launches; Rethinks How We Authenticate and Secure Identity
7. Fund launched to seed new thinking in sustaining the future of health
8. Researchers call for rethinking efforts to prevent interplanetary contamination
9. Major rethink needed if chemical industry is to meet greenhouse gas targets
10. A way of thinking may enable battle but prevent war crimes
11. Study prompts rethink of how ovaries develop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... of a small segment of DNA in the genome of ... of ancient animals from sea to land, or to later ... evidence" that copied DNA elements known as retroposons could be ... the research, Howard Hughes Medical Institute investigator David Haussler. ...
... the neighborhood bully so your buddy can get some tail ... works for some lizards, it also gives a fascinating peek ... their year on earth looking to reproduce, and their strategies ... edition of the Proceedings of the National Academy of Sciences ...
... along ?a siesta after a hearty lunch is natural, new ... for the first time uncovered how brain cells or 'neurons' ... , The findings ?published in the scientific journal Neuron this ... well as understanding levels of consciousness. , "It has been ...
Cached Biology News:Mobile DNA part of evolution's toolbox 2Mobile DNA part of evolution's toolbox 3Mobile DNA part of evolution's toolbox 4Nice guys do finish first in lizards' evolutionary race 2Why we could all do with a siesta 2
(Date:7/29/2015)... , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi ... patient recruitment services. The core expertise of PRC Clinical is focused on Clinical ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... cell culture products, announces the availability of BI’s line of human mesenchymal stem ... these stem cell differentiation media offer a complete system for multipotency evaluation of ...
(Date:7/28/2015)... , July 29, 2015 ... acquiring, rapidly developing and commercialising innovative ... health   Highly experienced management team; blue ...   Mereo BioPharma Group Ltd ("Mereo"), ... raised $119m ( c. £76.5m), gross, from blue chip ...
(Date:7/28/2015)... Nev. , July 28, 2015  PDL BioPharma, ... today announced that the Company will release its second ... 30, 2015, on Wednesday, August 5, 2015, after market ... webcast that day at 4:30 p.m. Eastern Time to ... the call will be available via the webcast link ...
Breaking Biology Technology:CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... ONTY ) today reported financial results for the three ... product pipeline update. Management will hold a conference call today ... details). , Oncothyreon reported a loss from operations of $2.8 ... with a loss from operations of $3.6 million for the ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: ... and advances a diverse portfolio of promising cancer-related products ... financial results for the first quarter of fiscal 2010, ... quarter, we continued to advance our lead drug nimotuzumab, ...
... MADRID, November 11 Cellerix, a product-focused,biopharmaceutical company ... the successful first closing of its financing round,raising EUR27 ... a select group of new investors. Cellerix completed another,financing ... This round was led by the ...
Cached Biology Technology:Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 2Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 3Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 4Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 5Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 6Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 7Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 2YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 3YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 4YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 5YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 6YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 7YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 9YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 10YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 11YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 12Cellerix Raises EUR27 Million in a First Closing 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Biology Products: